Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker



Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung cancer most likely to respond to the immunotherapy drug pembrolizumab (Keytruda®).



Source link

Comments are closed.